Taiji Asami

This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 7 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Takeda Chemical Industries, Inc.. Active years: 1999-2025.

USPTO Granted Patents = 19 (Patent Applications = 3)

% Patents Active = 73.7

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 48(Granted Patents)

Location History:

Tsukuba, JP (2007 - 2013)
Ibaraki, JP (1999 - 2014)
Fujisawa, JP (2015)
Kanagawa, JP (2015 - 2021)

Company Filing History:

18 out of 1,226

Takeda Pharmaceutical Company Limited

patents

1 out of 1,858

Takeda Chemical Industries, Inc.

patents

Years Active: 1999-2025

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202832 - Heterocyclic compounds having a calcium-sensing receptor antagonistic activity (2025-01-21),

2. 12122815 - GIP receptor agonist peptide compounds and uses thereof (2024-10-22),

3. 11174301 - Peptide compound (2021-11-16),

4. 10501516 - Peptide compound (2019-12-10),

5. 10435445 - Peptide compound (2019-10-08),

6. 10087229 - Peptide compound (2018-10-02),

7. 9260500 - Peptide and use thereof (2016-02-16),

8. 9200051 - Peptide compound (2015-12-01),

9. 9175037 - Neuromedin U derivative (2015-11-03),

10. 8778871 - Metastin derivatives and use thereof (2014-07-15),

11. 8765909 - Metastin derivatives and use thereof (2014-07-01),

12. 8404643 - Metastin derivatives and use thereof (2013-03-26),

13. 8361968 - Metastin derivatives and use thereof (2013-01-29),

14. 7960348 - Metastin derivatives and use thereof (2011-06-14),

15. 7786083 - Metastin derivatives and use thereof (2010-08-31),

Title: Innovations by Taiji Asami: A Pioneer in Pharmaceutical Patents

Introduction

Taiji Asami, an esteemed inventor based in Ibaraki, Japan, has made significant contributions to the pharmaceutical industry through his innovative research and development. With a remarkable total of 19 patents to his name, his work has largely focused on compounds that hold promise for treating various medical conditions.

Latest Patents

Among Taiji Asami's latest inventions are two notable patents:

1. **Heterocyclic Compounds Having a Calcium-Sensing Receptor Antagonistic Activity** - This invention relates to compounds or their salts that exhibit calcium-sensing receptor antagonistic activity. These compounds are anticipated to be beneficial in preventing or treating heart failure and pulmonary hypertension. The description outlines a specific formula representing these compounds, with detailed symbols as noted in the patent specification.

2. **GIP Receptor Agonist Peptide Compounds and Uses Thereof** - This patent introduces GIP receptor agonist peptide compounds that activate GIP receptors. These compounds are proposed as potential medicaments for treating and preventing diabetes, obesity, and related conditions. The patent specifies a particular peptide sequence represented in formula I, providing insights into its attributes and applications.

Career Highlights

Taiji Asami has contributed his expertise to notable companies such as Takeda Pharmaceutical Company Limited and Takeda Chemical Industries, Inc. His innovative work has been instrumental in advancing pharmaceutical technologies and enhancing therapeutic options available in healthcare.

Collaborations

Throughout his career, Asami has collaborated with other talented professionals, including Naoki Nishizawa and Ayumu Niida. These partnerships have fostered a dynamic environment for innovation, driving forward their shared vision for effective medical solutions.

Conclusion

Taiji Asami is a distinguished inventor whose work continues to shape the landscape of pharmaceutical advancements. His patents not only demonstrate the potential for treating complex medical conditions but also underscore the importance of collaboration and innovation in the field of medicine. As research progresses, Asami’s contributions will undoubtedly remain significant in the pursuit of improved health outcomes.